2 recruiting, 1 not yet recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow High-Risk Localized Prostate Cancer: new trials by email Literature Review of High-Risk Localized Prostate Cancer trials Research Report on High-Risk Localized Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RYZ711 Diagnostic Platform Study RYZ711, PSMA PET/CT - Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate | Phase 1 / Phase 2 | Not yet recruiting | RayzeBio, Inc. | 116 | 2026-10-01 | 2026-10-26 |
| PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT - High-Risk Localized Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-08-17 | 2026-09-22 |
| A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. Darolutamide, ADT - High-risk Localized Prostate Cancer | Phase 2 | Recruiting | Bayer | 250 | 2026-04-27 | 2026-10-13 |
Adenocarcinoma (1) · Prostatic Neoplasms (1)
Carcinoma (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Pluvicto (1) · darolutamide (1)
Bayer (1) · RayzeBio, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (2) · China (1)
Ana Kiess (1)